Fox Run Management L.L.C. Trims Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Fox Run Management L.L.C. lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,982 shares of the biopharmaceutical company’s stock after selling 7,668 shares during the quarter. Fox Run Management L.L.C.’s holdings in Catalyst Pharmaceuticals were worth $793,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CPRX. abrdn plc purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $10,115,000. Raymond James Financial Inc. purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $6,887,000. Skandinaviska Enskilda Banken AB publ raised its position in Catalyst Pharmaceuticals by 74.3% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after purchasing an additional 312,000 shares during the period. Jane Street Group LLC raised its position in Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Catalyst Pharmaceuticals in the third quarter valued at $4,936,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on CPRX. Bank of America restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $24.23 on Monday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84. The business has a fifty day moving average price of $22.39 and a 200 day moving average price of $21.63.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.